Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04463394 · ClinicalTrials.gov registry record · Early Phase 1
The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology
A Early Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
NCT04463394: Completed Early Phase 1 study, sponsored by Stanford University.
NCT04463394 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04463394, a Early Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate if vasopressin can elevate systemic arterial blood pressures without having a significant effect on pulmonary arterial pressures. Because patients who have undergone Fontan procedures rely on low pressures across the pulmonary vascular bed to maintain cardiac output, vasoactive agents that concomitantly increase systemic and pulmonary pressures may have a deleterious effect in this specific patient population. Hypothesis: In patients with Fontan physiology, vasopressin will increase systemic BP by 20% above baseline, without increasing the transpulmonary gradient.
Interventions
- DRUG Vasopressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2022-02-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04463394
The ClinicalTrials.gov registry entry for NCT04463394 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vasopressin is the first listed.
NCT04463394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04463394 about?
NCT04463394 is a clinical study titled "The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology". The goal of this study is to evaluate if vasopressin can elevate systemic arterial blood pressures without having a significant effect on pulmonary arterial pressures. Because patients who have undergone Fontan procedures rely on low pressures across the pulmonary vascular bed to maintain cardiac ou...
What is the current status of trial NCT04463394?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2020-08-12. Estimated completion is 2022-02-15.
What interventions are being tested in trial NCT04463394?
The interventions under investigation include: Vasopressin (DRUG).
Who is sponsoring clinical trial NCT04463394?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.